JP2022554175A5 - - Google Patents

Info

Publication number
JP2022554175A5
JP2022554175A5 JP2022523911A JP2022523911A JP2022554175A5 JP 2022554175 A5 JP2022554175 A5 JP 2022554175A5 JP 2022523911 A JP2022523911 A JP 2022523911A JP 2022523911 A JP2022523911 A JP 2022523911A JP 2022554175 A5 JP2022554175 A5 JP 2022554175A5
Authority
JP
Japan
Prior art keywords
item
composition according
virus
agonist
rlr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523911A
Other languages
English (en)
Japanese (ja)
Other versions
JP7707161B2 (ja
JP2022554175A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057099 external-priority patent/WO2021081353A1/en
Publication of JP2022554175A publication Critical patent/JP2022554175A/ja
Publication of JP2022554175A5 publication Critical patent/JP2022554175A5/ja
Priority to JP2025112246A priority Critical patent/JP2025138811A/ja
Application granted granted Critical
Publication of JP7707161B2 publication Critical patent/JP7707161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523911A 2019-10-23 2020-10-23 合成ｒｉｇ－ｉ様受容体アゴニスト Active JP7707161B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112246A JP2025138811A (ja) 2019-10-23 2025-07-02 合成ｒｉｇ－ｉ様受容体アゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962925120P 2019-10-23 2019-10-23
US62/925,120 2019-10-23
PCT/US2020/057099 WO2021081353A1 (en) 2019-10-23 2020-10-23 Synthetic rig-i-like receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112246A Division JP2025138811A (ja) 2019-10-23 2025-07-02 合成ｒｉｇ－ｉ様受容体アゴニスト

Publications (3)

Publication Number Publication Date
JP2022554175A JP2022554175A (ja) 2022-12-28
JP2022554175A5 true JP2022554175A5 (https=) 2023-10-31
JP7707161B2 JP7707161B2 (ja) 2025-07-14

Family

ID=73455800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523911A Active JP7707161B2 (ja) 2019-10-23 2020-10-23 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2025112246A Pending JP2025138811A (ja) 2019-10-23 2025-07-02 合成ｒｉｇ－ｉ様受容体アゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112246A Pending JP2025138811A (ja) 2019-10-23 2025-07-02 合成ｒｉｇ－ｉ様受容体アゴニスト

Country Status (8)

Country Link
US (1) US20220378817A1 (https=)
EP (1) EP4048795A1 (https=)
JP (2) JP7707161B2 (https=)
CN (1) CN115279905B (https=)
AU (1) AU2020372478A1 (https=)
CA (1) CA3155202A1 (https=)
MX (1) MX2022004825A (https=)
WO (1) WO2021081353A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
WO2025010306A2 (en) * 2023-07-03 2025-01-09 Biosolution Designs Vectors and methods for building polycistronic and/or multigenic transgenes

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US5287082A (en) 1992-07-02 1994-02-15 Cornell Research Foundation, Inc. Submicron isolated, released resistor structure
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CA2608579C (en) 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
HUE026153T2 (en) * 2008-05-21 2016-05-30 Rheinische Friedrich-Wilhelms-Universität Bonn 5'Triphosphate oligonucleotide with blunt end and uses thereof
WO2009141146A1 (en) * 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2014159990A1 (en) * 2013-03-13 2014-10-02 Yale University Interferon production using short rna duplexes
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014169049A1 (en) * 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
WO2015038746A1 (en) * 2013-09-11 2015-03-19 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expression
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
EP3172324A4 (en) * 2014-07-18 2018-04-25 Oregon Health & Science University 5'-triphosphate oligoribonucleotides
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
KR101674877B1 (ko) 2015-07-06 2016-11-14 한국해양과학기술원 결합장치를 구비한 무인선
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11382966B2 (en) * 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
GB201710642D0 (en) 2017-07-03 2017-08-16 Kromek Ltd Semiconductor detector geometry
BR112020020479A2 (pt) * 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
JP7366057B2 (ja) * 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト

Similar Documents

Publication Publication Date Title
JP2021521780A5 (https=)
JP5813778B2 (ja) トール様受容体に基づく免疫反応を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物
JP4383534B2 (ja) 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
EP2873674B1 (en) Chiral nucleic acid adjuvant
JP6023230B2 (ja) 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
EP3342415B1 (en) Structure and use of 5' phosphate oligonucleotides
KR20060033911A (ko) 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
JP2023109824A (ja) ＧａｌＮＡｃ誘導体
EP2437791B1 (en) Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
JP2006515277A (ja) Ｃ型肝炎ウィルス感染の処置および予防に関する方法および製品
JP2009533348A (ja) Ｔｌｒ７およびｔｌｒ８に対する安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物
US10023871B2 (en) Double-stranded polyC:poly(G/I) RNA for immunostimulation and cancer treatment
JP2022554175A5 (https=)
JP6698069B2 (ja) 免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
KR20150103739A (ko) 톨－유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 （ｉｒｏ） 화합물
Kandimalla et al. Agonists of Toll-like receptor 9: modulation of host immune responses with synthetic oligodeoxynucleotides
WO2024153142A1 (zh) CpG寡核苷酸及其应用
WO2026047025A1 (en) Photocontrollable conjugate, pharmaceutical composition and kit comprising the same, and uses thereof
IL324905A (en) TGFB2 agents against cancer with immunotherapy
EP4719437A1 (en) Connector modified synthetic rig-i agonists and methods of using the same
WO2025088117A1 (en) Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
TW202612708A (zh) 組合治療
WO2022104006A9 (en) Gpc3 aptamers and variants and use thereof
HK40045177A (en) Cpg amphiphiles and uses thereof
HK40045177B (en) Cpg amphiphiles and uses thereof